VOR Fundamental Analysis - VOR BIOPHARMA INC

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to VOR. VOR was compared to 547 industry peers in the Biotechnology industry. Both the profitability and financial health of VOR have multiple concerns. VOR is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year VOR has reported negative net income.

VOR had a negative operating cash flow in the past year.

VOR had negative earnings in each of the past 5 years.

In the past 5 years VOR always reported negative operating cash flow.

1.2 Ratios

VOR's Return On Assets of -810.45% is on the low side compared to the rest of the industry. VOR is outperformed by 97.07% of its industry peers.

		Industry Rank	Sector Rank
ROA	-810.45%
ROE	N/A
ROIC	N/A

ROA(3y)-57.36%

ROA(5y)-53.18%

ROE(3y)-78.63%

ROE(5y)-74.06%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VOR has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, VOR has more shares outstanding

There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

VOR has an Altman-Z score of -19.02. This is a bad value and indicates that VOR is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -19.02, VOR is not doing good in the industry: 83.18% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-19.02

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

VOR has a Current Ratio of 3.49. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.

VOR's Current ratio of 3.49 is in line compared to the rest of the industry. VOR outperforms 40.77% of its industry peers.

A Quick Ratio of 3.49 indicates that VOR has no problem at all paying its short term obligations.

VOR has a Quick ratio of 3.49. This is comparable to the rest of the industry: VOR outperforms 42.78% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.49
Quick Ratio	3.49

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for VOR have decreased strongly by -89.08% in the last year.

EPS 1Y (TTM)-89.08%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-434.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.34% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y26.21%

EPS Next 2Y33.87%

EPS Next 3Y11.76%

EPS Next 5Y15.34%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VOR. In the last year negative earnings were reported.

Also next year VOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y33.87%

EPS Next 3Y11.76%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for VOR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VOR BIOPHARMA INC

NASDAQ:VOR (8/26/2025, 8:06:50 PM)

Premarket: 2.15 +0.07 (+3.37%)

2.08

+0.02 (+0.97%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-12 2025-08-12/amc

Earnings (Next)11-05 2025-11-05/amc

Inst Owners46.53%

Inst Owner Change-5.77%

Ins Owners11.18%

Ins Owner Change24.9%

Market Cap263.49M

Analysts71.11

Price Target1.2 (-42.31%)

Short Float %26.07%

Short Ratio0.85

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-203.61%

Min EPS beat(2)-394.6%

Max EPS beat(2)-12.62%

EPS beat(4)1

Avg EPS beat(4)-114.56%

Min EPS beat(4)-394.6%

Max EPS beat(4)1.46%

EPS beat(8)3

Avg EPS beat(8)-56.67%

EPS beat(12)4

Avg EPS beat(12)-37.97%

EPS beat(16)7

Avg EPS beat(16)-26.51%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-86.73%

EPS NQ rev (1m)23.82%

EPS NQ rev (3m)65.99%

EPS NY rev (1m)-76.42%

EPS NY rev (3m)-92.56%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-3.29

EYN/A

EPS(NY)-0.35

Fwd EYN/A

FCF(TTM)-0.9

FCFYN/A

OCF(TTM)-0.9

OCFYN/A

SpS0

BVpS-11.89

TBVpS-11.89

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-810.45%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-57.36%

ROA(5y)-53.18%

ROE(3y)-78.63%

ROE(5y)-74.06%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	10.68%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.49
Quick Ratio	3.49
Altman-Z	-19.02

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)123.83%

Cap/Depr(5y)265.1%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-89.08%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-434.15%

EPS Next Y26.21%

EPS Next 2Y33.87%

EPS Next 3Y11.76%

EPS Next 5Y15.34%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-194.38%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.68%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-31.56%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-32.69%

OCF growth 3YN/A

OCF growth 5YN/A

VOR BIOPHARMA INC (VOR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens